Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Liabilities (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Total Liabilities data on record, last reported at $82.4 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 14.24% year-over-year to $82.4 million; the TTM value through Sep 2025 reached $82.4 million, up 14.24%, while the annual FY2024 figure was $78.9 million, 4.33% down from the prior year.
  • Total Liabilities reached $82.4 million in Q3 2025 per SGMO's latest filing, up from $78.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $407.7 million in Q1 2021 and bottomed at $69.3 million in Q2 2024.
  • Average Total Liabilities over 5 years is $188.4 million, with a median of $91.4 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 114.72% in 2021, then plummeted 70.23% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $346.6 million in 2021, then fell by 22.8% to $267.6 million in 2022, then plummeted by 69.19% to $82.4 million in 2023, then decreased by 4.33% to $78.9 million in 2024, then rose by 4.48% to $82.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $82.4 million in Q3 2025, $78.0 million in Q2 2025, and $81.3 million in Q1 2025.